Alnylam Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALNY research report →
About the company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders.
- CEO
- Yvonne L. Greenstreet
- IPO
- 2004
- Employees
- 2,230
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $41.76B
- P/E
- 72.01
- P/S
- 9.74
- P/B
- 38.65
- EV/EBITDA
- 44.70
- Div Yield
- 0.00%
- Gross Margin
- 80.89%
- Op Margin
- 17.54%
- Net Margin
- 13.46%
- ROE
- 98.29%
- ROIC
- 19.66%
- Revenue
- $3.71B · 65.19%
- Net Income
- $313.75M · 212.79%
- EPS
- $2.39 · 209.63%
- Op Income
- $501.58M
- FCF YoY
- 1192.73%
- 52W High
- $495.55
- 52W Low
- $273.11
- 50D MA
- $295.83
- 200D MA
- $366.93
- Beta
- 0.27
- Avg Volume
- 1.14M
Get TickerSpark's AI analysis on ALNY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 1, 26 | PYOTT DAVID E I | other | 3,830 |
| Jun 1, 26 | PYOTT DAVID E I | sell | 921 |
| Jun 1, 26 | PYOTT DAVID E I | sell | 1,175 |
| Jun 1, 26 | PYOTT DAVID E I | sell | 1,222 |
| Jun 1, 26 | PYOTT DAVID E I | sell | 495 |
| Jun 1, 26 | PYOTT DAVID E I | sell | 17 |
| Jun 1, 26 | PYOTT DAVID E I | other | 3,830 |
| Jun 1, 26 | Cravatt Benjamin | other | 4,393 |
| Jun 1, 26 | Cravatt Benjamin | other | 0 |
| May 20, 26 | Sigal Charles Elliott | other | 671 |
Our ALNY coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ALNY?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.